Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC ...

Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted into mice. The Kobe University development is a significant contribution towards faster and cheaper cancer ...

Researchers say their achievement represents an important step toward the development of a new immunotherapy for solid tumors ...

Verismo Therapeutics, a clinical-stage multi-chain CAR T cell therapy company pioneering a novel KIR-CAR platform technology, today announced a new preclinical KIR-CAR program targeting the clinically ...

Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted in mice. The Kobe University development is a significant contribution toward faster, cheaper cancer immunotherapy.

Wistar Institute scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian ...

Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of ...

Body composition modulations during cyclic fasting-mimicking diet in patients with advanced solid cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

The cutting edge of treating solid tumors with cell therapies got notably sharper this year. As the director of Solid Tumor Cell Therapy and leader of Stanford Medicine’s Melanoma and Cutaneous ...

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors ...

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first ...

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months ...